IP Library Granted Patent US 8,492,146
Granted Patent B2
US 8,492,146 · App. 13/265,942 · Granted Jul 23, 2013

Process for producing a human T-cell population having both cytotoxic and immunosuppressive activities

Inventors: Takeshi Otani (Okayama, JP); Makoto Takeuchi (Okayama, JP); Shuji Nakamura (Okayama, JP); Fumiyuki Yamasaki (Okayama, JP)
Assignee: Hayashibara Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,492,146
App. No.
13/265,942
Granted
Jul 23, 2013
Kind
B2
Abstract

A human T cell population which has both cytotoxic and immunosuppressive activities, is efficiently produced by first fractionating CD2-positive CD14-negative cells from mononuclear cells collected from a human umbilical cord blood, and then co-culturing them with stromal cells. The resulting blast cells, which have the desired activity, are proliferated by further culture.

Claims (8)

1. A method for producing a human T cell population which has both cytotoxic and immunosuppressive activities, said method comprising the following steps (1) to (5):

(1) fractionating mononuclear cells collected from a human umbilical cord blood into CD14-positive (CD14 + ) cells and CD14-negative (CD14) cells, and then fractionating the CD14-negative (CD14) cells into CD2-positive CD14-negative (CD2′ CD14) cells, and CD2-negative CD14-negative (CD2 − CD14) cells;

(2) co-culturing the CD2-positive CD14-negative (CD2 + CD14) cells obtained in step (1) with stromal cells to differentiate the CD2-positive CD14-negative (CD2 + CD14 − ) cells into blast cells which have both cytotoxic and immunosuppressive activities;

(3) co-culturing the CD14-positive (CD14 + ) cells obtained in step (1) with fresh stromal cells to differentiate the CD14-positive (CD14 + ) cells into cells capable of promoting the proliferation of the blast cells;

(4) adding the blast cells obtained in step (2) to the resulting co-culture of step (3) to proliferate the blast cells obtained in step (2); and

(5) co-culturing the blast cells obtained in step (4) with fresh stromal cells in medium supplemented with interleukin-2 (IL-2) to further proliferate,

thereby producing a human T cell population which has both cytotoxic and immunosuppressive activities.

2. The method of claim 1 , wherein in co-culturing with said stromal cells step (2), said CD2-positive CD14-negative (CD2 + CD14 − ) cells are inoculated at a cell density of 6.2×10 5 /cm 2 in terms of the bottom surface area of each well.

Assignments (2)
MERGER Recorded Jun 20, 2013
From: KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENYUJO
To: HAYASHIBARA CO., LTD.
Reel/Frame 030649/0755 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2012
From: OTANI, TAKESHI; TAKEUCHI, MAKOTO; NAKAMURA, SHUJI; YAMASAKI, FUMIYUKI
To: KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO
Reel/Frame 027689/0136 →
Priority Claims (1)
JP 2009-106311 · Apr 24, 2009 · national
Continuity (1)
Related Publication 20120040454A1 · Feb 16, 2012